Study

EORTC-2418-GUCG-STARBURST 1

Multimodal strategies to define Clinical Response to neoadjuvant therapy in Muscle-invasive Bladder Cancer (Starburst-1)

Trial Status

Regulatory in Process

Dates

Data management at EORTC

Yes

Design

Cohort
Not randomized / N.A.

Targeted Sample size

EORTC Groups: 240 - All Groups: 240

Study Staff

  • Alexandra Masson Lecomte (Study Coordinator), APHP Nord - Univ De Paris Cite - Hop. Saint Louis, Paris
  • Yves Allory (Study Co-Coordinator), Institut Curie - l' Hopital de St Cloud, Saint-Cloud
  • Thierry Nicolas Boellaard (Study Co-Coordinator), The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam
  • Lars Dyrskjot (Study Co-Coordinator), Region Midtjylland - Aarhus University Hospital-Skejby, Aarhus
  • Valeria Panebianco (Study Co-Coordinator), Azienda ospedaliero Univ Policlinico Umberto I, Roma
  • Guillaume Grisay (Y-ECI Coordinator), CHU Helora Pole Hospitalier Jolimont - Hopital Jolimont, Haine-Saint-Paul
  • Tina Verschuere (Project Manager), EORTC Headquarters, Brussels
  • Bert Dhondt (Clinical Research Physician), EORTC Headquarters, Brussels
  • Beatrice Fournier (Medical representative), EORTC Headquarters, Brussels
  • Cedric Mallien (TR Scientist), EORTC Headquarters, Brussels
  • Florence Dujardin (Junior Clinical Operations Manager), EORTC Headquarters, Brussels
  • Camila Matiollo (Data Manager), EORTC Headquarters, Brussels
  • Axelle Nzokirantevye (Imaging DM), EORTC Headquarters, Brussels
  • Jelle Stans (Regulatory Affairs Manager), EORTC Headquarters, Brussels
  • Anja Mestnik (Junior RAM), EORTC Headquarters, Brussels
  • Lucy Sepulveda (Junior RAM), EORTC Headquarters, Brussels
  • Shyamala Rajarajacholan (Clinical Operations Assistant), EORTC Headquarters, Brussels
  • Olga Basova (Senior Statistician), EORTC Headquarters, Brussels

Type of cancer

  • Bladder

Participating groups

  • EORTC Genito-Urinary Cancers Group

Centers to be activated

  • APHP Centre - Univ de Paris Cite - Hopital Europeen Georges Pompidou (PARIS, France)
  • APHP Sorbonne Univ - Hopital la Pitie-Salpetriere (Paris, France)
  • AZ Groeninge Kortrijk - Campus Kennedylaan (Kortrijk, Belgium)
  • AZ Maria Middelares (Gent, Belgium)
  • Azienda ospedaliero Univ Policlinico Umberto I (Roma, Italy)
  • CHU Helora Pole Hospitalier Jolimont - Hopital Jolimont (Haine-Saint-Paul, Belgium)
  • CHU de Lille - Hopital Huriez (Lille, France)
  • Clinique La Croix Du Sud (Quint-Fonsegrives, France)
  • Clinique Pasteur-Toulouse (Toulouse, France)
  • Cliniques Universitaires Saint-Luc (Brussels, Belgium)
  • IRCCS - Fondazione Istituto Nazionale dei Tumori (Milano, Italy)
  • IRCCS Ospedale San Raffaele (Milano, Italy)
  • IRCCS-Regina Elena National Cancer Center (Roma, Italy)
  • Institut Bergonie (Bordeaux, France)
  • Institut Jules Bordet (Anderlecht, Belgium)
  • Institut Paoli-Calmettes (Marseille, France)
  • Institut de Cancerologie de Lorraine (Vandoeuvre les Nancy, France)
  • The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis (Amsterdam, Netherlands)
  • Vilnius University Hospital Santaras Clinics Branch-National Cancer Center (Vilnius, Lithuania)

Protocol summary

NCT number

NCT02834884

Study

EORTC-2418-GUCG-STARBURST 1

Multimodal strategies to define Clinical Response to neoadjuvant therapy in Muscle-invasive Bladder Cancer (Starburst-1)

Linked Studies

EORTC-1553-SPECTA

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access